Lacosamide Tablet, Film Coated
Product Images NDC 65862-747

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 65862-747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose)

A bar chart titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' comparing placebo and lacosamide at various doses across three studies. The vertical axis shows median seizure reduction percentage from 0% to 45%. Each study shows bars for placebo and lacosamide doses with corresponding sample sizes and percent reductions, highlighting statistically significant differences marked by asterisks.*

FDA Label Image

Package Label-principal Display Panel (200 mg (3 x 10) Unit-dose Tablets)

Carton label for Lacosamide Tablets, USP 200 mg oral film-coated tablets by Aurobindo Pharma Limited. The package contains 30 unit-dose tablets (3 blister cards of 10 tablets each). The label includes dosage strength, unit-dose packaging information, NDC 65862-750-03, storage instructions, and distributor details for Aurobindo Pharma USA, Inc.*

FDA Label Image

Figure 2 (Proportion of Patients by Response Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4.' The x-axis represents the percent of patients from 0 to 100, and the y-axis shows responder rate from -100% (worsening) to 100% (improvement). Four lines represent different groups: placebo, Lacosamide 200 mg/day, Lacosamide 400 mg/day, and Lacosamide 600 mg/day. The graph illustrates the distribution of patient responder rates across these groups.*

FDA Label Image

Package Label-principal Display Panel (50 mg (60 Tablets Bottle))

Lacosamide Tablets, USP 50 mg film-coated tablets label by Aurobindo Pharma Limited. The label displays NDC 65862-747-60 and indicates a package size of 60 tablets. It includes dosage form and strength, storage instructions at controlled room temperature, distributor information, and a barcode on the right side.*

FDA Label Image

Package Label-principal Display Panel (50 mg (3 x 10) Unit-dose Tablets)

Packaging label for Lacosamide Tablets, USP 50 mg film-coated oral tablets by Aurobindo Pharma Limited. The package contains 30 unit-dose tablets (3 strips of 10). The label includes dosage strength, manufacturer information, storage instructions, and notes that the unit-dose package is not child resistant.*

FDA Label Image

Package Label-principal Display Panel (100 mg (60 Tablets Bottle))

Label for Lacosamide Tablets USP 100 mg film-coated tablets by Aurobindo Pharma Limited. The label indicates prescription use, contains dosing and storage instructions, and specifies packaging of 60 tablets. Distributed by Aurobindo Pharma USA, Inc., with manufacturing origin noted as Made in India.*

FDA Label Image

Package Label-principal Display Panel (100 mg (3 x 10) Unit-dose Tablets)

Lacosamide Tablets, USP 100 mg film-coated tablets packaging label from Aurobindo Pharma Limited. The label indicates 30 unit-dose tablets arranged as 3 blister cards of 10 tablets each. The label includes storage instructions, a warning that the unit-dose package is not child resistant, and provides the distributor information as Aurobindo Pharma USA, Inc.*

FDA Label Image

Package Label-principal Display Panel (150 mg (60 Tablets Bottle))

Label for Lacosamide Tablets USP 150 mg, film-coated oral tablets. The label indicates a quantity of 60 tablets and includes the National Drug Code (NDC) 65862-749-60. Distributed by Aurobindo Pharma USA, Inc., made in India. Storage instructions specify controlled room temperature of 20° to 25°C (68° to 77°F). The label includes a note for the pharmacist to dispense the Medication Guide separately to each patient.*

FDA Label Image

Package Label-principal Display Panel (150 mg (3 x 10) Unit-dose Tablets)

Packaging label for Lacosamide Tablets, USP 150 mg film-coated oral tablets distributed by Aurobindo Pharma USA, Inc. The label states the package contains 30 unit-dose tablets (3 x 10) and includes storage instructions and a pharmacist medication guide note. The label features the Aurobindo logo and specifies the product is prescription only.*

FDA Label Image

Package Label-principal Display Panel (200 mg (60 Tablets Bottle))

Label for Lacosamide Tablets USP 200 mg film-coated tablets, oral use. The label shows the active ingredient lacosamide, strength 200 mg, packaged as 60 tablets. It is distributed by Aurobindo Pharma USA, Inc. and made in India. Storage instructions specify 20° to 25°C (68° to 77°F). The label includes a National Drug Code (NDC) 65862-750-60 and notes the product is for prescription use only.*

FDA Label Image

Str (Lacosamide Str)

Chemical structure diagram of the active ingredient Lacosamide, showing its molecular bonds and functional groups as part of the drug's molecular formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.